Updates are available Correction dated 2024-01-05
Click to view Correction: https://doi.org/10.1038/s43018-023-00719-4
-
Authors
Zhou, Caicun http://orcid.org/0000-0002-6958-0766
Wang, Ziping
Sun, Meili
Cao, Lejie
Ma, Zhiyong
Wu, Rong
Yu, Yan
Yao, Wenxiu
Sun, Si
Chen, Jianhua
Zhuang, Wu
Cui, Jiuwei
Chen, Xueqin
Lu, You http://orcid.org/0000-0003-1671-1408
Shen, Hong
Hu, Chunhong
Liu, Jiwei
Liu, Yunpeng
Wang, Mengzhao
Li, Xingya
Sun, Ping
Shu, Yongqian
Zhou, Jianying
Li, Jingzhang
Gu, Kangsheng
Wang, Changli
Zhao, Hui
Zhang, Yiping
Liu, Chunling
Wang, Jingru
Chen, Rumei
Qin, Mengmeng
Wang, Hao
Yang, Jason
- License Information
-
More Information
Article History
Received: 14 September 2022
Accepted: 12 May 2023
First Online: 15 June 2023
Change Date: 5 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-023-00719-4
Competing interests
: C.Z. reports speaker honoraria from CStone Pharmaceuticals during the course of this study and, outside this study, reports speaker honoraria from Lilly China, Sanofi, Boehringer Ingelheim, Roche, MSD, Qilu Pharmaceutical, Jiangsu Hengrui Therapeutics, Innovent Bio, Luye Pharma Group, TopAlliance Biosciences and Amoy Diagnostics; he is an adviser for Innovent Bio, Jiangsu Hengrui Therapeutics, Qilu Pharmaceutical and TopAlliance Biosciences. J.W., R.C., M.Q., H.W. and J.Y. are paid employees of CStone Pharmaceuticals. J.W. and J.Y. declare stock ownership in the company. The other authors declare no competing interests.
